ReviewDrugs2022
Tapinarof Cream 1%: First Approval.
Review in Drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 67 citations in OpenAlex.
- Skin Relevant Biomaterials from Wound Healing, Medical Aesthetics, Flexible Electronics to Artificial Intelligence and Beyond.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.Pharmacological reviews · 2026Review
- T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets.Aging cell · 2026Review
- Article
- The aryl hydrocarbon receptor: structure, signaling, physiology and pathology.Signal transduction and targeted therapy · 2026Review
- ALDH3A1-dependent Nrf2/HO-1/GPX4 pathway supports AHR as a promising therapeutic target for ferroptosis and promotes imperatorin-mediated lung protection.Cell death discovery · 2026Article
- A Novel HDAC6 Inhibitor Ameliorates Imiquimod-Induced Psoriasis-Like Inflammation in Mice.Molecules (Basel, Switzerland) · 2025Article
- Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.Journal of clinical medicine · 2025Review
- Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy.Scientific reports · 2025Article
- Tapinarof Nanogels as a Promising Therapeutic Approach.Pharmaceutics · 2025Review
- Tapinarof Cream 1%: Pediatric First Approval.Paediatric drugs · 2025Review
- Monocytes Expressing IL-36G Play a Crucial Role in Atopic Dermatitis.Journal of cellular and molecular medicine · 2025Article
- Review
- Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis.Pharmaceutics · 2024Review
- Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis.Gels (Basel, Switzerland) · 2024Article
- New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.Pharmaceutics · 2024Review
- Aryl hydrocarbon receptor role in chronic inflammatory skin diseases: a narrative review.Postepy dermatologii i alergologii · 2024Review
- Article
- Topical Prescription Management.Advances in experimental medicine and biology · 2024Review
- Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.Dermatology practical & conceptual · 2023Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tapinarof cream 1% (VTAMA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.